Treatment of Erectile Dysfunction in Patients with Postural Orthostatic Tachycardia Syndrome (POTS)

First-Line Treatment

The American College of Cardiology recommends starting with phosphodiesterase type 5 inhibitors (PDE5i) as first-line therapy for erectile dysfunction (ED) in patients with POTS, while addressing POTS-specific factors such as depression screening, volume optimization, and medication review 1
PDE5 inhibitors, including sildenafil, tadalafil, vardenafil, and avanafil, should be initiated regardless of whether the ED has psychological or physical origins, with a dosing strategy that starts conservatively and titrates to maximum dose 1
An adequate trial of PDE5i requires at least 5 separate occasions at maximum dose before declaring treatment failure, with success rates reaching 60-65% for achieving successful intercourse 1
The weighted mean percentage of successful intercourse attempts is 69% with sildenafil, 68% with vardenafil, and 69% with tadalafil, compared to 33-35% with placebo 2

The American Heart Association recommends implementing lifestyle modifications, including smoking cessation, weight loss if BMI >30 kg/m², increased physical activity, reduced alcohol consumption, and optimization of any comorbid conditions, concurrently with PDE5i initiation 1
Obtaining morning serum total testosterone level is essential for all men with ED, and if testosterone is documented as low, consider testosterone replacement therapy 3

If two different PDE5i trials at maximum dose fail, refer to urology for intraurethral alprostadil suppositories, intracavernous vasoactive drug injection therapy, or vacuum erection devices, which have an initial efficacy of 90% but satisfaction drops to 50-64% at 2 years 4

Educate the patient that if he experiences anginal chest pain after taking PDE5i, he should seek immediate medical attention and inform providers that at least 48 hours must elapse after the last PDE5i dose before nitrate administration 3